ProQR Therapeutics (PRQR) Operating Expenses (2012 - 2026)

ProQR Therapeutics has reported Operating Expenses for 15 years, with the latest figure at $18.4 million in Q1 2026.

• Quarterly Operating Expenses rose 12.19% year-over-year to $18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.5 million (up 28.4% YoY) and the FY2025 annual result came in at $69.6 million, up 30.22% from the prior year.
• Operating Expenses eased to $18.4 million in Q1 2026 per PRQR's latest filing, from $123.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $127.9 million in Q4 2022 and troughed at -$20.9 million in Q3 2022.
• A 5-year average of $17.0 million and a median of -$10.8 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 729.12% in 2022, then slumped 69.5% in 2025.
• Over 5 years, Operating Expenses stood at $127.9 million in 2022, then tumbled by 40.88% to $75.6 million in 2023, then rose by 20.83% to $91.4 million in 2024, then soared by 34.75% to $123.1 million in 2025, then tumbled by 85.09% to $18.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $18.4 million, $123.1 million, and -$16.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.